Forte Biosciences Inc FBRX
Set alert
76.99 USD 0.00 0.00%
At close · Aug 26
21.03 -55.96 -72.68%
After hours · Aug 26, 4:00 PM ET
76.96 Day range 77.00
10.11 52-week range 77.20
- YTD
- +182.32%
- 1 year
- +574.76%
- Open
- 76.97
- Prev close
- 76.99
- Mkt cap
- 1.63B
- Vol
- 1.40M
- Avg vol
- 1.51M
- EPS
- -4.57
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 76.96
- High
- 77.00
- Forward P/E
- -18.89
- Beta
- 2.65
- Short ratio
- 0.82
- Inst. own
- 96.65%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 13, 2026
- 50-d avg
- 55.18
- 200-d avg
- 33.25
- 1y target
- 73.00
Key statistics
- Market cap
- 1.63B
- Enterprise value
- 1.74B
- Trailing P/E
- 0.00
- Forward P/E
- -18.89
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 10.24
- EPS (TTM)
- -4.57
- Beta
- 2.65
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -41.29M
- Total cash
- 198.46M
- Total debt
- 0
- Return on equity
- -62.28%
- Shares outstanding
- 21.23M
- Short % of float
- 7.74%
- 50-day average
- 55.18
- 200-day average
- 33.25
Analyst view
Consensus: buy
Buy
Price target (mean) 73.00 -5.2% downside
Now 76.99
- Target (low)
- 61.00
- Target (mean)
- 73.00
- Target (high)
- 77.00
Ratings (0m) 4 1 buy · 3 hold · 0 sell
- Strong buy0
- Buy1
- Hold3
- Sell0
- Strong sell0
Next earnings
Nov 13, 2026
Expected Nov 13, 2026. Consensus EPS estimate -1.09.
Financials — quick view
FBRX Revenue — quarterly 0
FBRX Net income — quarterly -23.33M
FBRX EPS — quarterly -0.97
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2026 | Sep 30, 2026 | -0.90 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -1.08 | -0.97 | +0.11 | +10.19% |
| May 21, 2026 | Mar 31, 2026 | -1.16 | -1.24 | -0.08 | -6.90% |
| Mar 31, 2026 | Dec 31, 2025 | -1.42 | -1.45 | -0.03 | -2.11% |
| Nov 14, 2025 | Sep 30, 2025 | -1.04 | -0.99 | +0.05 | +4.81% |
| Aug 14, 2025 | Jun 30, 2025 | -1.21 | -0.96 | +0.25 | +20.66% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 28, 2026 | Barclays | down | Overweight | Equal-Weight |
| Jul 21, 2026 | Barclays | init | — | Overweight |
| Nov 25, 2025 | Evercore ISI Group | init | — | Outperform |
| Nov 17, 2025 | Chardan Capital | main | Buy | Buy |
| Aug 18, 2025 | Guggenheim | init | — | Buy |
| Aug 15, 2025 | Chardan Capital | main | Buy | Buy |
About Forte Biosciences Inc
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fortebiorx.com
News
- Alger Dynamic Opportunities Fund Q3 2026 Portfolio Update
- Squarepoint Ops LLC Reduces Position in Forte Biosciences, Inc. $FBRX
- argenx Completes Acquisition of Forte Biosciences, Inc.
- Are SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders?
- Are SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders?
- Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
- Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
- FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders
- FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders
- The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—FBRX, LXFR, SMTI, and MKTX
Your note
Sign in to keep a note on FBRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| RILEY ANTONY A | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 30, 2026 | 42,600 |
| WAGNER PAUL A | Chief Executive Officer | Conversion of Exercise of derivative security | Jun 30, 2026 | 85,482 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes, Inc. | 9.94% | 2,110,516 | 162.49M | Jun 29, 2026 |
| Orbimed Advisors LLC. | 7.43% | 1,577,705 | 121.47M | Jun 29, 2026 |
| Fred Alger Management, LLC | 6.78% | 1,439,697 | 110.84M | Jun 29, 2026 |
| Jupiter Topco LLC | 6.47% | 1,373,060 | 105.71M | Jun 29, 2026 |
| Blackrock Inc. | 5.76% | 1,222,862 | 94.15M | Jun 29, 2026 |
| Affinity Asset Advisors, Llc | 5.40% | 1,145,391 | 88.18M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 5.90% | 1,251,500 | 96.35M | Apr 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 4.36% | 924,891 | 71.21M | Jul 30, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 3.92% | 832,100 | 64.06M | Apr 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.93% | 622,927 | 47.96M | Jun 29, 2026 |
| ALGER FUNDS-Alger Small Cap Focus Fund | 2.34% | 496,062 | 38.19M | Apr 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.16% | 457,916 | 35.25M | Jun 29, 2026 |